Contact

Allergyauthority.com serves as a reference resource covering allergy diagnosis, treatment frameworks, regulatory context, and safety standards across the United States. This page explains how to direct inquiries to the editorial office, what geographic scope the resource addresses, what information to include when submitting a message, and what response timelines are typical. Understanding this structure helps ensure inquiries are routed correctly and handled efficiently.

How to reach this office

The editorial office for Allergyauthority.com accepts written inquiries submitted through the contact form attached to this page by the site template. Written submissions are the single supported channel for all inquiry types, including factual corrections, source challenges, editorial suggestions, and accessibility concerns.

No telephone or postal channel is maintained for general public inquiries. This structure is consistent with guidance from the Federal Trade Commission's guidance on digital consumer communication and aligns with standard editorial practices for reference-grade health information properties operating under the National Institutes of Health's published principles for online health resource quality (NIH, MedlinePlus editorial standards framework).

Inquiry categories accepted:

1. Factual corrections — Identified errors in cited statistics, misattributed regulatory citations, or outdated clinical classifications.
2. Source challenges — Requests to verify or update a named public source, including agency documents, peer-reviewed publications, or statute references.
3. Editorial suggestions — Proposals for topics not yet covered, including emerging allergy subtypes, updated allergy research and advances, or gaps in allergy statistics in the US.
4. Accessibility concerns — Issues with content readability, screen-reader compatibility, or structural compliance under Section 508 of the Rehabilitation Act (29 U.S.C. § 794d).
5. Licensing and republication requests — Formal requests to reproduce page content in third-party publications, requiring written approval.

Inquiries that fall outside these five categories — including requests for personalized medical advice, clinical referrals, or emergency guidance — cannot be addressed through this channel. For emergency allergy events, including suspected anaphylaxis, the appropriate resource is 911 or a licensed emergency medical facility.

Service area covered

Allergyauthority.com covers allergy-related topics within the scope of United States regulatory, clinical, and epidemiological frameworks. The primary regulatory references used throughout the site include the U.S. Food and Drug Administration (for drug approvals, epinephrine auto-injectors, and food allergy labeling laws), the Centers for Disease Control and Prevention (for prevalence data and public health framing), and the American Academy of Allergy, Asthma & Immunology (AAAAI) clinical practice parameters.

Content is written to national scope, meaning it reflects federal statutes and guidelines rather than state-specific legislation unless a specific state comparison is directly relevant. Allergy prevalence data draws primarily from CDC National Health Interview Survey (NHIS) figures and FDA labeling mandates under the Food Allergen Labeling and Consumer Protection Act (FALCPA), enacted in 2004. The site does not produce jurisdiction-specific legal guidance for individual states.

The resource addresses allergy subtypes across 4 major classification domains:

• Immune-mediated (IgE-mediated): food allergies, insect sting allergies, drug allergies, latex allergies
• Respiratory/environmental: seasonal allergies, pet allergies, dust mite allergies, mold allergies
• Cutaneous: skin allergies and contact dermatitis, eczema and atopic dermatitis
• Complex or comorbid: allergic asthma, eosinophilic esophagitis, oral allergy syndrome

Inquiries that fall outside US regulatory scope — for example, questions about European Medicines Agency (EMA) approvals or non-US food labeling standards — may receive limited editorial responses.

What to include in your message

A well-structured inquiry reduces back-and-forth and accelerates editorial review. The following five components are required for all substantive submissions:

1. Inquiry type — Identify which of the five accepted categories listed above applies.
2. Specific page URL or slug — Reference the exact page under question (e.g., /allergy-testing-methods or /skin-prick-test) rather than describing it in general terms.
3. The specific claim in question — Quote the exact sentence, statistic, or citation being challenged or questioned.
4. Supporting source — Provide the name of the public document, agency publication, peer-reviewed journal, or statute that contradicts or supplements the existing content. Sources without a named public origin cannot be evaluated.
5. Contact address for follow-up — Provide a functional email address so the editorial team can confirm receipt or request clarification.

Incomplete submissions that omit items 2 through 4 are deprioritized in the review queue. Submissions that include personal health histories, symptom descriptions, or requests for a diagnosis cannot be processed and will not be forwarded to any clinical party.

Response expectations

Editorial review operates on a structured queue. Factual corrections referencing a named public source — such as a CDC NHIS table, an FDA drug approval record, or a FALCPA statutory provision — are reviewed within 10 business days of receipt. Source challenges requiring cross-referencing against peer-reviewed literature may require up to 20 business days, depending on the complexity of the claim.

Licensing and republication requests are reviewed on a separate track with a standard 15 business-day initial response window. Accessibility concerns flagged under Section 508 are treated as priority submissions and reviewed within 5 business days in alignment with federal accessibility compliance norms.

Submissions are not acknowledged by automated receipt email unless the site template generates one. If no response is received within the stated window, resubmission with a note referencing the original submission date is appropriate. The editorial office does not guarantee a response to inquiries that do not meet the completeness criteria outlined above or that fall outside the five accepted categories.

Privacy Policy

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)